Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC2) weekly in combination with paclitaxel 80 mg/m^2 followed by dose dense doxorubicin cyclophosphamide therapy for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.

This is written in the approval document as:

Neoadjuvant treatment of triple negative breast carcinoma

Citation

CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/734-carboplatin-auc-2-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-cyclophosphamide-therapy-triple-negative-breast-cancer-therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel